Organon Llc patents expiration
1. Asmanex Hfa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5889015 | ORGANON LLC | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US6365581 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US6057307 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
|
US5889015 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
|
US6057307 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
|
US6365581 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
| US6068832 | ORGANON LLC | Chlorofluorocarbon-free mometasone furoate aerosol formulations |
Aug, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 12, 2022 |
| Pediatric Exclusivity(PED) | Feb 12, 2023 |
Drugs and Companies using MOMETASONE FUROATE ingredient
Market Authorisation Date: 12 August, 2019
Treatment: Treatment of asthma
Dosage: AEROSOL, METERED;INHALATION
ASMANEX HFA family patents
2. Asmanex Twisthaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5394868 (Pediatric) | ORGANON LLC | Inhalation device for powdered medicaments |
Dec, 2012
(11 years ago) | |
| US6057307 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US5889015 | ORGANON LLC | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US6949532 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US6677322 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US6365581 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
|
US5889015 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
|
US6365581 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
|
US6677322 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
|
US6949532 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
|
US6057307 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
| US5687710 | ORGANON LLC | Inhaler for powdered medications having spiral deagglomeration chamber |
Nov, 2014
(9 years ago) | |
|
US5687710 (Pediatric) | ORGANON LLC | Inhaler for powdered medications having spiral deagglomeration chamber |
May, 2015
(8 years ago) | |
| US5829434 | ORGANON LLC | Inhaler for powdered medications |
Nov, 2015
(8 years ago) | |
|
US5829434 (Pediatric) | ORGANON LLC | Inhaler for powdered medications |
May, 2016
(8 years ago) | |
| US6240918 | ORGANON LLC | Powdered medication inhaler |
Feb, 2017
(7 years ago) | |
|
US6240918 (Pediatric) | ORGANON LLC | Powdered medication inhaler |
Aug, 2017
(6 years ago) | |
| US8173172 | ORGANON LLC | Preparation of powder agglomerates |
Mar, 2018
(6 years ago) | |
| US6503537 | ORGANON LLC | Preparation of powder agglomerates |
Mar, 2018
(6 years ago) | |
|
US6503537 (Pediatric) | ORGANON LLC | Preparation of powder agglomerates |
Sep, 2018
(5 years ago) | |
|
US8173172 (Pediatric) | ORGANON LLC | Preparation of powder agglomerates |
Sep, 2018
(5 years ago) | |
Drugs and Companies using MOMETASONE FUROATE ingredient
Market Authorisation Date: 01 February, 2008
Treatment: Treatment of asthma
Dosage: POWDER;INHALATION
ASMANEX TWISTHALER family patents
3. Clarinex-d 12 Hour patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214684 | ORGANON LLC | Methods for the treatment of allergic rhinitis |
Dec, 2014
(9 years ago) | |
| US7214683 | ORGANON LLC | Compositions of descarboethoxyloratadine |
Dec, 2014
(9 years ago) | |
|
US7214684 (Pediatric) | ORGANON LLC | Methods for the treatment of allergic rhinitis |
Jun, 2015
(8 years ago) | |
|
US7214683 (Pediatric) | ORGANON LLC | Compositions of descarboethoxyloratadine |
Jun, 2015
(8 years ago) | |
| US6100274 | ORGANON LLC | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jul, 2019
(4 years ago) | |
|
US6100274 (Pediatric) | ORGANON LLC | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jan, 2020
(4 years ago) | |
| US7618649 | ORGANON LLC | Extended release oral dosage composition |
Dec, 2020
(3 years ago) | |
| US8187630 | ORGANON LLC | Extended release oral dosage composition |
Dec, 2020
(3 years ago) | |
| US6709676 | ORGANON LLC | Extended release oral dosage composition |
Feb, 2021
(3 years ago) | |
|
US7618649 (Pediatric) | ORGANON LLC | Extended release oral dosage composition |
Jun, 2021
(2 years ago) | |
Drugs and Companies using DESLORATADINE; PSEUDOEPHEDRINE SULFATE ingredient
Market Authorisation Date: 01 February, 2006
Treatment: Treatment of allergic rhinitis; A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis; Allergic rhinitis
Dosage: TABLET, EXTENDED RELEASE;ORAL
CLARINEX-D 12 HOUR family patents
4. Dulera patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6057307 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US5889015 | ORGANON LLC | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US6677323 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
|
US6057307 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
|
US5889015 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
| US6068832 | ORGANON LLC | Chlorofluorocarbon-free mometasone furoate aerosol formulations |
Aug, 2017
(6 years ago) | |
| US7566705 | ORGANON LLC | Combination of formoterol and mometasone furoate for asthma |
May, 2020
(3 years ago) | |
| US7067502 | ORGANON LLC | Combinations of formoterol and mometasone furoate for asthma |
May, 2020
(3 years ago) | |
|
US7067502 (Pediatric) | ORGANON LLC | Combinations of formoterol and mometasone furoate for asthma |
Nov, 2020
(3 years ago) | |
|
US7566705 (Pediatric) | ORGANON LLC | Combination of formoterol and mometasone furoate for asthma |
Nov, 2020
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-214) | Dec 20, 2020 |
| New Strength(NS) | Aug 12, 2022 |
| Pediatric Exclusivity(PED) | Jun 20, 2021 |
| New Combination(NC) | Jun 22, 2013 |
Drugs and Companies using FORMOTEROL FUMARATE; MOMETASONE FUROATE ingredient
Market Authorisation Date: 12 August, 2019
Treatment: Treatment of asthma
Dosage: AEROSOL, METERED;INHALATION
DULERA family patents
5. Fosamax Plus D patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5358941 | ORGANON LLC | Dry mix formulation for bisphosphonic acids with lactose |
Dec, 2012
(11 years ago) | |
| US5681590 | ORGANON LLC | Dry mix formulation for bisphosphonic acids |
Dec, 2012
(11 years ago) | |
| US6090410 | ORGANON LLC | Dry mix formulation for bisphosphonic acids |
Dec, 2012
(11 years ago) | |
|
US5681590 (Pediatric) | ORGANON LLC | Dry mix formulation for bisphosphonic acids |
Jun, 2013
(10 years ago) | |
|
US5358941 (Pediatric) | ORGANON LLC | Dry mix formulation for bisphosphonic acids with lactose |
Jun, 2013
(10 years ago) | |
|
US6090410 (Pediatric) | ORGANON LLC | Dry mix formulation for bisphosphonic acids |
Jun, 2013
(10 years ago) | |
| US5994329 | ORGANON LLC | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
|
US5994329 (Pediatric) | ORGANON LLC | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
Drugs and Companies using ALENDRONATE SODIUM; CHOLECALCIFEROL ingredient
Market Authorisation Date: 07 April, 2005
Treatment: Treatment of osteoporosis in post menopausal women and/or the treatment to increase bone mass in men with osteoporosis
Dosage: TABLET;ORAL
FOSAMAX PLUS D family patents
6. Maxalt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5602162 (Pediatric) | ORGANON LLC | Imidazole, triazole and tetrazole derivatives |
Jul, 2012
(11 years ago) | |
|
US5298520 (Pediatric) | ORGANON LLC | Triazole containing indole derivatives |
Dec, 2012
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 16, 2015 |
| New Patient Population(NPP) | Dec 16, 2014 |
Drugs and Companies using RIZATRIPTAN BENZOATE ingredient
Market Authorisation Date: 29 June, 1998
Treatment: NA
Dosage: TABLET;ORAL
MAXALT family patents
7. Nasonex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6723713 | ORGANON LLC | Use of mometasone furoate for treating upper airway diseases |
Jan, 2014
(10 years ago) | |
| US5837699 | ORGANON LLC | Use of mometasone furoate for treating upper airway passage diseases |
Jan, 2014
(10 years ago) | |
|
US5837699 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating upper airway passage diseases |
Jul, 2014
(9 years ago) | |
|
US6723713 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating upper airway diseases |
Jul, 2014
(9 years ago) | |
| US6127353 | ORGANON LLC | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
Oct, 2017
(6 years ago) | |
|
US6127353 (Pediatric) | ORGANON LLC | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
Apr, 2018
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-99) | Jan 19, 2014 |
| New Indication(I-626) | May 26, 2013 |
Drugs and Companies using MOMETASONE FUROATE ingredient
Market Authorisation Date: 01 October, 1997
Treatment: Allergic rhinitis or nasal polyps
Dosage: SPRAY, METERED;NASAL
NASONEX family patents
8. Xaciato patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11129896 | ORGANON LLC | Topical formulations and treatments |
Sep, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 07, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Dec 07, 2029 |
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 07 December, 2021
Treatment: Method of treating bacterial vaginosis by single dose administration of a clindamycin pharmaceutical gel formulation
Dosage: GEL;VAGINAL
XACIATO family patents